Anbio Biotechnology
NNNN
3 hedge funds and large institutions have $496K invested in Anbio Biotechnology in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.15% more ownership
Funds ownership: 0% → 0.15% (+0.15%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$298K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$117K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$39.2K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Marshall Wace
London,
United Kingdom
| $325K | +$298K | +43,629 | New |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $127K | +$117K | +17,060 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| $42.8K | +$39.2K | +5,738 | New |
|
NNNN Hedge Fund Activity: Q1 2025 in Review
3 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Anbio Biotechnology (NNNN) for Q1 2025, worth a combined $496K.
Buyers outnumbered sellers: 3 funds opened new NNNN positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Marshall Wace, opening a new position worth an estimated $298K.
- 3 institutional investors held Anbio Biotechnology (NNNN) as of Q1 2025, up from 0 in Q4 2024.
- Funds reported $496K of Anbio Biotechnology stock for Q1 2025.
- 3 funds opened new Anbio Biotechnology positions in Q1 2025 and 0 closed out, a net change of +3 holders.
- The largest Anbio Biotechnology buyer in Q1 2025 was Marshall Wace, an estimated $298K added.
Based on aggregated 13F filings for Q1 2025.